Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748773 | 0.84 | PIK3CA (0.41) | PIK3CAMAPTL3MBTL1SMN1; SMN2INSR | |
| SCHEMBL30749097 | 0.82 | MAPT (0.44) | PIK3CAMAPTL3MBTL1SMN1; SMN2INSR | |
| SCHEMBL30748786 | 0.80 | PSEN1 (0.43) | MAPTSMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL30749134 | 0.78 | LRRK2 (0.43) | PIK3CAINSRALKLRRK2MEN1 | |
| SCHEMBL15333995 | 0.75 | PIK3CA (0.42) | PIK3CAINSRALKLRRK2PIK3CD | |
| SCHEMBL30749056 | 0.74 | TTK (0.43) | PIK3CAMAPTINSRALKLRRK2 | |
| SCHEMBL28088687 | 0.72 | MAPT (0.40) | MAPTL3MBTL1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30748930 | 0.71 | TTK (0.42) | PIK3CAMAPTINSRALKLRRK2 | |
| SCHEMBL15333353 | 0.70 | INSR (0.51) | MAPTINSRALKLRRK2PIK3CB | |
| SCHEMBL31691453 | 0.69 | PIK3CA (0.36) | PIK3CAMAPTL3MBTL1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | PIK3CA 1906/4885MAPT 3029/4885L3MBTL1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.